This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| pancreatic adenocarcinoma | |
|---|---|
| Name | Pancreatic adenocarcinoma |
| Field | Oncology, Surgery, Gastroenterology |
| Symptoms | Jaundice, abdominal pain, weight loss |
| Complications | Metastasis, cachexia, biliary obstruction |
| Onset | Middle to late adulthood |
| Duration | Variable |
| Causes | Genetic mutations, smoking, chronic pancreatitis |
| Risks | Smoking, diabetes mellitus, obesity |
| Diagnosis | Imaging, biopsy, serum markers |
| Treatment | Surgery, chemotherapy, radiotherapy, targeted therapy |
pancreatic adenocarcinoma is an aggressive exocrine malignancy arising from the pancreatic ductal epithelium that presents with nonspecific systemic and local manifestations and carries a poor prognosis. Historically a focus of research at institutions such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Johns Hopkins Hospital, it has driven advances in surgical techniques pioneered by figures associated with Whipple procedure proponents and chemotherapy regimens developed through trials at National Cancer Institute and European Organisation for Research and Treatment of Cancer. Contemporary management integrates contributions from oncology groups like American Society of Clinical Oncology and European Society for Medical Oncology and draws on diagnostics from centers including Massachusetts General Hospital and Royal Marsden Hospital.
Patients typically present with painless jaundice, epigastric pain radiating to the back, and unexplained weight loss; these symptoms prompt evaluation in clinics linked to Cleveland Clinic, Royal Victoria Hospital, and John Radcliffe Hospital. Other manifestations include new-onset diabetes, anorexia, steatorrhea, and pruritus, often leading referrals to specialists at Guy's and St Thomas' NHS Foundation Trust, Karolinska University Hospital, and Toronto General Hospital. Paraneoplastic phenomena and thromboembolic events, including migratory thrombophlebitis observed historically in cases studied at Mayo Clinic and Mount Sinai Hospital (New York City), may precede diagnosis and involve multidisciplinary teams from American College of Surgeons and European Association for the Study of the Liver. Cachexia and biliary obstruction complications frequently necessitate interventions available at tertiary centers like UCSF Medical Center and Stanford Health Care.
On a molecular level, tumorigenesis commonly involves activating mutations in KRAS and inactivation of CDKN2A (p16), TP53, and SMAD4, findings reported in landmark studies affiliated with University of Texas MD Anderson Cancer Center and Cold Spring Harbor Laboratory. Progression from pancreatic intraepithelial neoplasia to invasive carcinoma mirrors models developed by investigators at Cancer Research UK and Dana–Farber Cancer Institute, reflecting dysregulated signaling in pathways studied by researchers at Broad Institute and Sanger Institute. Tumor-stroma interactions, desmoplastic reaction, and dense extracellular matrix—areas explored at Karolinska Institutet and Vanderbilt University Medical Center—impair drug delivery and immune infiltration, concepts also central to immunotherapy research at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center. Metastatic tropism to the liver, peritoneum, and lungs follows mechanisms investigated in collaborative projects involving Wellcome Sanger Institute and Institut Pasteur.
Diagnostic evaluation integrates cross-sectional imaging, endoscopic techniques, and histopathology practiced at high-volume centers such as Mayo Clinic and Johns Hopkins Hospital. Contrast-enhanced computed tomography by radiology departments at Massachusetts General Hospital and Royal Brompton Hospital is first-line for detection and staging, while endoscopic ultrasound with fine-needle aspiration performed by teams at Asan Medical Center and Seoul National University Hospital provides tissue diagnosis. Serum CA 19-9 assessment, standardized in laboratories following guidelines from College of American Pathologists and Clinical and Laboratory Standards Institute, aids monitoring but lacks specificity, prompting adjunctive PET-CT usage in centers like Memorial Sloan Kettering Cancer Center and Royal Marsden Hospital. Multidisciplinary tumor boards at institutions such as University College London Hospitals and University of California, Los Angeles synthesize pathology reports, including immunohistochemical profiling influenced by protocols from The Royal College of Pathologists.
Staging uses the TNM system promulgated by the AJCC Cancer Staging Manual and applied in clinical trials run by groups including EORTC and SWOG. Resectability categories—resectable, borderline resectable, locally advanced, and metastatic—are determined by vascular involvement assessments standardized at centers like Memorial Sloan Kettering Cancer Center and Mayo Clinic. Prognosis remains poor with 5-year survival influenced by stage at diagnosis, margin status after resections at institutions performing Whipple procedure and distal pancreatectomy, and molecular features identified in cohorts from MD Anderson and Dana–Farber Cancer Institute. Predictive biomarkers under investigation at Broad Institute and Sanger Institute seek to refine prognostication and guide precision therapies developed with partners such as Genentech and Novartis.
Curative-intent resection, including pancreaticoduodenectomy popularized in historical series linked to Whipple procedure proponents, is offered at high-volume surgical centers like Johns Hopkins Hospital, Mayo Clinic, and Mount Sinai Hospital (New York City). Perioperative and adjuvant chemotherapy regimens (FOLFIRINOX, gemcitabine-based) were tested in trials by ASCO, EORTC, and NCI cooperative groups and are administered at oncology units including MD Anderson Cancer Center and Royal Marsden Hospital. Neoadjuvant approaches for borderline disease employ protocols from German Cancer Research Center and National Cancer Center Hospital (Japan), while radiation therapy techniques are implemented at MD Anderson and Memorial Sloan Kettering Cancer Center. Palliative interventions—endoscopic stenting, biliary bypass, pain management—are performed at centers such as Cleveland Clinic and UCSF Medical Center, and emerging targeted and immunotherapies are subjects of trials run by European Medicines Agency-registered sponsors and biotechnology firms like Bristol Myers Squibb and Pfizer.
Incidence and mortality statistics are tracked by agencies including World Health Organization, Centers for Disease Control and Prevention, and Global Burden of Disease Study, which show rising absolute numbers with aging populations. Established risk factors include tobacco exposure documented in cohorts from Framingham Heart Study-related analyses, chronic pancreatitis studied at Karolinska University Hospital, hereditary syndromes linked to BRCA2 and PALB2 mutations characterized in pedigrees from University of Utah and University of Pennsylvania, and diabetes mellitus patterns explored in studies from Harvard T.H. Chan School of Public Health. Obesity and dietary factors have been investigated in prospective cohorts coordinated by Nurses' Health Study and Physicians' Health Study.
Primary prevention emphasizes tobacco cessation policies advocated by World Health Organization Framework Convention proponents, weight control guidance from National Institutes of Health, and management of chronic pancreatitis in clinics such as Mayo Clinic. Population-based screening is not recommended for average-risk individuals by panels from USPSTF and American Cancer Society, but surveillance programs for high-risk cohorts (hereditary pancreatitis, familial pancreatic cancer) are run at specialized centers including Johns Hopkins Hospital, University of Pittsburgh Medical Center, and Vanderbilt University Medical Center using MRI and endoscopic ultrasound according to protocols developed with input from International Cancer of the Pancreas Screening (CAPS) Consortium. Ongoing trials and registries coordinated by National Cancer Institute and Cancer Research UK evaluate biomarkers and imaging strategies to enable earlier detection.